January 25, 2026

Bangalore, India, Jan 24: OneSource Speciality Pharma Limited today announced its consolidated financial results for the quarter ended December 31, 2025 (Q3FY26).

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “As previously anticipated, this has been a subdued quarter due to delays in customer approvals in Canada that have prolonged the transition from the MSA to the CSA phase. The inherent demand, however, remains intact with order book continuing to trend upwards. In our nascent biologics segment, we continue to witness strong interest, with another global biosimilar player onboarded and the funnel at a historic high.”

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Spykar announces unique Republic Day campaign recognizing India’s changemakers
Next post HCLTech to acquire Singapore-based Finergic to boost digital transformation offerings for wealth management industry